Cardio-vascular
Refine Search
Pharmaceutical
Canadian drugmaker Valeant Pharmaceuticals International has responded to a letter from US Senator Claire McCaskill (Democrat, Missouri) concerning pricing of the company's products Nitropress (nitroprusside) and Isuprel (isoproterenol). 15 October 2015
Pharmaceutical
Eli Lilly has announced that all clinical trials involving its atherosclerosis drug candidate evacetrapib are being halted. 12 October 2015
Biotechnology
Pharmacy benefit manager Express Scripts has announced it will cover both Repatha (evolocumab) from Amgen and Praluent (alirocumab) from Regeneron, two PCSK9 inhibitors. 7 October 2015
Biotechnology
Wales-based biotech company Cell Therapy will begin the application process for a conditional European marketing authorization for Heartcel. 5 October 2015
Pharmaceutical
AtriCure, a US innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, has entered into a definitive agreement to acquire nContact, a North Carolina, privately held developer of innovative cardiac ablation solutions. 5 October 2015
Pharmaceutical
More real-world safety data, especially in patients with a high risk of cardiovascular disease, could potentially address the issue of under-dosing and under-treatment with novel oral anticoagulants (NOACs) in global practice, says an analyst. 29 September 2015
Pharmaceutical
Quebec-based pharma company Valeant is the target of US lawmakers seeking to take action over price increases of its cardiovascular drugs, sending shares sliding 20%. 29 September 2015
Biotechnology
The European Commission has granted marketing authorization for Praluent (alirocumab) for the treatment of low-density lipoprotein (LDL) cholesterol, in certain adult patients with hypercholesterolemia. 28 September 2015
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s Xarelto (rivaroxaban) for an additional indication, the treatment and secondary prevention of pulmonary thromboembolism and deep vein thrombosis. 25 September 2015
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Swiss pharma giant Novartis’ Entresto (sacubitril/valsartan). 25 September 2015
Pharmaceutical
ReNeuron Group on Thursday said it expects data from its treatment candidate for disability caused by ischaemic stroke in the first half of 2016. 24 September 2015
Pharmaceutical
Swiss pharma giant Novartis today announced the launch of “Novartis Access,” a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. 24 September 2015
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lixiana (edoxaban) from Daiichi Sankyo to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. 23 September 2015
Pharmaceutical
Armetheon has entered into an agreement with China Cardiovascular Focus, a subsidiary of Lee's Pharmaceutical, to initiate advanced-stage clinical testing, manufacturing and commercialization of Armetheon's investigational oral anticoagulant, tecarfarin, in the greater China market including Mainland China, Hong Kong, Macau, and Taiwan as well as Thailand. 22 September 2015
Pharmaceutical
Novartis announced today that Swissmedic has approved Entresto (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). 18 September 2015
Pharmaceutical
New research has shown that Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of care in patients with type 2 diabetes at high risk of CV events. 18 September 2015
Pharmaceutical
Chinese specialty drugmaker Yabao Pharmaceutical has entered into an exclusive license with privately held Canadian firm Primary Peptides to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke. 17 September 2015
Biotechnology
Amgen has entered into a definitive acquisition agreement to acquire Dezima, a privately-held, Netherlands-based biotechnology company focused on developing innovative treatments for dyslipidemia. 16 September 2015
Biotechnology
US biotech company Amgen has submitted a marketing application to the US Food and Drug Administration for a once-a-month dosing of Repatha (evolocumab). 15 September 2015
Pharmaceutical
A new report offers a comprehensive review of currently-available evidence on two new interventions that have triggered significant interest as potential advances in the care of patients with congestive heart failure (CHF). 15 September 2015
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze